Medbio LLC02.22.19
Medbio LLC, a contract manufacturer specializing in cleanroom injection molding of plastic components for the medical and biotechnology industries, has acquired AIM Plastics Inc. Medbio is a portfolio company of Graham Partners, a private investment firm targeting industrial technology and advanced manufacturing companies. Headquartered outside of Detroit, Michigan, AIM is a founder-owned medical device component manufacturer offering full-service injection molding and in-house tooling capabilities to high-growth therapeutic areas within the healthcare sector. AIM specializes in the rapid turnaround of prototype-to-production molds and complex injection molding that requires niche medical expertise.
The founders of AIM were attracted to Medbio and Graham Partners' operating resources in the healthcare space, as well as the cultural fit and potential commercial and operational synergies between AIM and Medbio. The successful acquisition of AIM represents a major step forward in Graham's investment thesis to build a premier medical device manufacturing business. AIM adds highly complementary capabilities to the Medbio platform, adding scale and increasing customer and end market diversification. AIM also provides additional manufacturing capacity needed to support the growth of the combined business.
Joe Heinmiller, managing principal at Graham Partners, stated, "AIM is a truly transformative add-on acquisition for Medbio. We are looking forward to combining these two industry-leading businesses into a larger, more diversified medical device outsourced manufacturer with additional capabilities."
Steven Graham, CEO of Graham Partners, added, "Graham is excited to increase our exposure in this attractive industry niche and leverage our resources in the industry to continue Medbio's strong growth trajectory."
The founders of AIM were attracted to Medbio and Graham Partners' operating resources in the healthcare space, as well as the cultural fit and potential commercial and operational synergies between AIM and Medbio. The successful acquisition of AIM represents a major step forward in Graham's investment thesis to build a premier medical device manufacturing business. AIM adds highly complementary capabilities to the Medbio platform, adding scale and increasing customer and end market diversification. AIM also provides additional manufacturing capacity needed to support the growth of the combined business.
Joe Heinmiller, managing principal at Graham Partners, stated, "AIM is a truly transformative add-on acquisition for Medbio. We are looking forward to combining these two industry-leading businesses into a larger, more diversified medical device outsourced manufacturer with additional capabilities."
Steven Graham, CEO of Graham Partners, added, "Graham is excited to increase our exposure in this attractive industry niche and leverage our resources in the industry to continue Medbio's strong growth trajectory."